4 results
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
The purpose of the study is to evaluate how effective rilzabrutinib is and how safe it is, in reducing the signs and symptoms in patients with chronic spontaneous urticaria (CSU), who continue to have symptoms despite the use of H1-antihistamines (…
Phase 1• To establish the RP2D regimen by evaluation of the safety and tolerability of intravenous (IV) administration of Lutetium (177Lu) rhPSMA-10.1 injection in subjects with mCRPC.Phase 2• To evaluate the efficacy of Lutetium (177Lu) rhPSMA-10.1…
Primary Efficacy Objective (Blinded Treatment Period)• To demonstrate the efficacy of rilzabrutinib versus placebo in participants with refractory/relapsed ITP, based on the durability of platelet response during the last12 weeks of the 24-week…